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 A novel synthetic, host-defence peptide protects against organ 
injury/dysfunction in a rat-model of severe hemorrhagic shock 
 
Background: Hemorrhagic shock (HS) is still a common cause of death in severely injured 
patients. However, there is no specific pharmacological intervention that prevents MOF associated 
with HS. The underlying pathophysiology is characterized by impairment of organ perfusion and 
systemic inflammatory response, both of which triggers the release of endogenous host-
defence/antimicrobial peptides. 
Objective: To evaluate (i) levels of the host-defence/antimicrobial peptide LL-37 in patients with 
trauma and HS (ii) the effects of a synthetic host-defence peptide (Pep19-4LF) on MOF associated 
with HS in rats.  
Methods: (i) LL-37 was measured in 47 trauma/hemorrhage patients (ISS-score greater than or 
equal to 16) admitted to an urban major trauma center, and 10 healthy volunteers. (ii) Male Wistar 
rats were submitted to HS or sham operation. HS was induced by withdrawal of blood from a 
catheter implanted in the carotid artery to reduce mean arterial blood pressure (MAP) to 
approximately 30 mmHg for 90 min. At 90 min after initiation of hemorrhage (or when 25% of the 
shed blood had to be re-injected to sustain target MAP), resuscitation was performed with the 
shed blood over a period of 5 min. The same volume of blood for maintenance of MAP was 
replaced by Ringer lactate on resuscitation. Rats were treated with Pep19-4LF [66 (n=8) or 
333μg/kg x h (n=8)] or vehicle (n=12) for 4 h following resuscitation. 
Results: Plasma LL-37 was 12-fold higher in patients with trauma/hemorrhage compared to 
healthy volunteers. When compared to trauma patients, the plasma levels of LL-37 were 
significantly higher in trauma hemorrhage patients. Increased levels were associated with (a) low 
systolic blood pressure, (b) high heart rate, (c) high lactate, and (d) low base deficit on admission. 
HS-rats treated with high dose Pep19-4LF had a significant higher MAP at the end of the 4 h 
resuscitation period (79±4 vs. 54±5 mmHg). Pep19-4LF treatment (high dose) resulted in 
significantly attenuated renal dysfunction, liver injury and lung inflammation compared to HS-rats 
treated with vehicle. Pep19-4LF enhanced (kidney/liver) the phosphorylation of (i) protein kinase 
B and (ii) endothelial nitric oxide synthase. Moreover, Pep19-4LF (high dose) attenuated the HS-
induced (i) translocation of p65 from cytosol to nucleus, (ii) phosphorylation of IKK on Ser176/180 
and (iii) phosphorylation of IκBα on Ser32/36 resulting in inhibition of NF- B and formation of pro-
inflammatory cytokines. 
Conclusions: Trauma-associated HS results in the release of LL-37. The synthetic host-
defence/antimicrobial peptide Pep19-4LF attenuates the organ injury/dysfunction associated with 
HS. Thus, Pep19-4LF may be useful to reduce MOF caused by severe hemorrhage and 
resuscitations in patients with trauma. 
 
